| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022) | Nurix Therapeutics, Inc. | 2022-04-13 |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma (NCT05144347) | Exelixis | 2022-04-12 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (NCT04895436) | AbbVie | 2022-03-28 |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (NCT05168930) | Dana-Farber Cancer Institute | 2022-02-18 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05105841) | AbbVie | 2021-11-08 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137) | Nurix Therapeutics, Inc. | 2021-05-05 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (NCT04767308) | Huazhong University of Science and Technology | 2021-03-01 |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL (NCT04685915) | Inhye Ahn | 2021-02-18 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia (NCT04655261) | AbbVie | 2020-12-12 |
| The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) (NCT04447768) | Memorial Sloan Kettering Cancer Center | 2020-12-03 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT04209621) | National Heart, Lung, and Blood Institute (NHLBI) | 2020-07-31 |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (NCT04285567) | Hoffmann-La Roche | 2020-05-28 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax (NCT04419519) | Memorial Sloan Kettering Cancer Center | 2020-05-13 |
| A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) (NCT04198415) | AbbVie | 2020-02-03 |
| Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (NCT03788291) | University of Rochester | 2019-03-25 |
| A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation (NCT03873857) | AbbVie | 2019-02-25 |
| Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (NCT03824483) | Memorial Sloan Kettering Cancer Center | 2019-02-22 |
| A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (NCT03659669) | AbbVie | 2019-02-10 |
| Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors (NCT03771157) | University of Rochester | 2019-02-01 |
| Dietary Intervention With High Phenolic EVOO in CLL (NCT04215367) | University of Peloponnese | 2018-12-15 |
| Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) (NCT03702231) | National Heart, Lung, and Blood Institute (NHLBI) | 2018-12-07 |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies (NCT03588598) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-09-07 |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy (NCT03406156) | AbbVie | 2018-08-10 |
| Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (NCT03580928) | Dana-Farber Cancer Institute | 2018-08-07 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib (NCT03400176) | Novartis Pharmaceuticals | 2018-04-09 |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (NCT03342144) | AbbVie | 2017-12-04 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT02966756) | AbbVie | 2017-10-12 |
| Evaluation of the Immune Restoration Potential Of Lenalidomide (NCT02371577) | University of California, San Diego | 2017-02-01 |
| A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (NCT02980731) | AbbVie | 2016-12-13 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (NCT02914938) | MEI Pharma, Inc. | 2016-10-01 |
| Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL (NCT02580552) | miRagen Therapeutics, Inc. | 2016-02-09 |
| Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (NCT02538614) | Gilead Sciences | 2015-12-29 |
| Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients (NCT02553304) | National Health Research Institutes, Taiwan | 2015-09-01 |
| informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (NCT02582879) | Pharmacyclics LLC. | 2015-09-01 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies (NCT02265731) | AbbVie | 2014-09-22 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (NCT02226861) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-26 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs (NCT02200380) | Celldex Therapeutics | 2014-07-01 |
| A Phase II Study of Doxycycline in Relapsed NHL (NCT02086591) | University of Rochester | 2014-03-01 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT01976520) | XEME Biopharma Inc. | 2013-10-01 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT01463852) | Dartmouth-Hitchcock Medical Center | 2012-10-01 |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) (NCT01580228) | Merck Sharp & Dohme LLC | 2012-08-01 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (NCT01413568) | Polyphor Ltd. | 2012-04-01 |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) (NCT01520922) | Novartis Pharmaceuticals | 2012-03-01 |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (NCT01723839) | Hackensack Meridian Health | 2012-02-22 |
| A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT01466153) | MedImmune LLC | 2012-02-07 |
| An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) (NCT01532700) | University Health Network, Toronto | 2012-02-01 |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) (NCT01419691) | University of Kansas Medical Center | 2011-09-01 |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL (NCT01203930) | Gilead Sciences | 2010-10-01 |
| Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia (NCT01188681) | Aptevo Therapeutics | 2010-09-01 |
| Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (NCT01241786) | Hackensack Meridian Health | 2010-07-01 |
| Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab (NCT01125787) | Nevada Cancer Institute | 2010-05-01 |
| Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment (NCT01087333) | National Cancer Institute (NCI) | 2010-03-02 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (NCT01050764) | Everett Meyer | 2009-06-01 |
| The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL (NCT00919321) | Tampere University Hospital | 2009-06-01 |
| Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (NCT00840853) | Baylor College of Medicine | 2009-04-01 |
| Tumor Registry of Lymphatic Neoplasia (NCT00889798) | iOMEDICO AG | 2009-04-01 |
| Unrelated Umbilical Cord Blood (UBC)Transplantation (NCT01768845) | West Virginia University | 2009-02-03 |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies (NCT00710528) | Gilead Sciences | 2008-06-01 |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00694590) | Genzyme, a Sanofi Company | 2008-06-01 |
| Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) (NCT00640523) | BioCryst Pharmaceuticals | 2008-03-01 |
| Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma (NCT00614042) | Aptevo Therapeutics | 2008-01-01 |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia (NCT00664677) | Erimos Pharmaceuticals | 2007-08-01 |
| Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00439231) | Georg Aue, M.D. | 2007-02-01 |
| Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (NCT00458679) | Baylor College of Medicine | 2006-12-01 |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia (NCT00230282) | Steven E. Coutre | 2004-07-01 |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |
| Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia (NCT02136511) | Gilead Sciences | |